ANNOUNCED AS TEMPORARYNo
With Resolution of the Russian Government N 91 of 17 February 2011 was approved the Federal Programme titled 'Development of the Pharmaceutical and Medical Industry of the Russian Federation for the period up to 2020 and its farther perspective'. The purpose of the Programme is to finance and ensure the transition of the Russian pharmaceutical and medical industry to an innovative model of development.
The overall financing of the programme from the federal budget is at the amount of 122.6 billion RUB (3.1 billion EUR). This figure is to be allocated in the period 2011--2020 among the following major categories:
In addition to budgetary funds, the programme is expected to receive 1.6 billion EUR of investments from other sources.
The principal implementation measures related to the programme are divided into seven groups:
Some of the target indicators related to the programme are trade-related including:
The affected foreign jurisdictions are identified on the basis of the country of origin of the top foreign pharma companies that operate on the Russian market (see Annex 2 of the 2nd provided source for more details).
The GTA includes state guarantees and other financial incentives thatare likely to affect the restructuring and performance of firms facinginternational competition, whether from imports, in export markets, andfrom foreign subsidiaries.
⚑ Please report this page in case you detect an inaccuracy in its content.